Breast Cancer Feasibility
Research type
Research Study
Full title
Breast Cancer Treatment Patterns using Real World Data in the UK
IRAS ID
236072
Contact name
Joseph Kim
Contact email
Sponsor organisation
Novartis Pharmaceuticals Corporation
Duration of Study in the UK
0 years, 3 months, 25 days
Research summary
Breast cancer is the most common cancer in the UK. Research has indicated that patients may respond better to certain treatments based on characteristics of their cells. These patients represent a smaller group of all breast cancer patients. Newer treatments can target specific cells to improve patients' lives in these smaller groups of patients. However, little research has been done to determine which treatments these patients receive and how this may affect their lives.
This study will look at whether there are enough patients within a smaller group of breast cancer patients (hormone receptor positive/epidermal growth factor negative/postmenopausal) available within the Cancer Analysis System (CAS) to study which treatments these patients receive and how often they go to the hospital.
REC name
London - Stanmore Research Ethics Committee
REC reference
17/LO/1856
Date of REC Opinion
3 Nov 2017
REC opinion
Further Information Favourable Opinion